HNST · Honest
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $4.70
Note written ·
How this view changed
- · Rated Medium. Results, 5 November 2026: Q3 2026 organic revenue grew 9.2%, underlying adjusted gross margin reached 48.9%, FY2026 guidance was raised and a new $30 million buyback was approved.
Price against the kill line
6.7% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $4.70, on record since 10 November 2026. The shares are up 6.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $4.70, which would give back most of the gain since the $4.44 close on 5 November 2026, the day of the third-quarter report. A cut to the 2026 outlook (6–7% organic growth, 45.5–46.5% adjusted gross margin) would also break the case.
Research onlyNot in the portfolio.
Key figures from the filings · Consumer Discretionary
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 84.6
- Revenue, change on a year (%)
- −8.6
- Gross margin (%)
- 45.0
- Operating margin (%)
- 1.4
- Free cash flow, four quarters ($M)
- 48.6
- Net cash, cash less debt ($M)
- 103
- Price to earnings (×)
- 7.0
- Enterprise value to sales (×)
- 1.3
All filed numbers
What Honest reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 84.6 | −8.6 | 45.0 | 1.4 |
| first filed | 83.3 | −10.9 | 48.4 | 11.5 |
| first filed | 78.1 | −19.7 | 42.6 | −0.8 |
| first filed | 88.0 | −11.8 | 15.7 | −27.5 |
| first filed | 92.6 | −6.7 | 37.3 | 0.3 |
| first filed | 93.5 | +0.4 | 40.4 | 3.1 |
| Pre-tax income ($M) | 1.9 |
| Net income ($M) four quarters: 78.4 | 91.3 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −1.1 |
| Operating cash flow ($M) | 52.6 |
| Capital spending ($M) | 4.0 |
| Free cash flow ($M) | 48.6 |
| Cash and short-term investments ($M) | 103 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 103 |
| Deferred revenue ($M) at 31 December 2025, filed 25 February 2026; −100.0% on a year | 0.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 44.9 |
| Inventory ($M) | 52.5 |
| Shareholders' equity ($M) | 263 |
| Market value ($M) | 547 |
| Enterprise value, market value plus net debt ($M) no debt reported | 444 |
| Enterprise value to sales (×) no debt reported | 1.3 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | 7.0 |
| Price to book value (×) | 2.1 |
| Free-cash-flow yield (%) | 8.9 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 8.7% of shares outstanding sold short, 7.0 days of average trading to cover, −6.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $1.2M |
| 12 monthsfrom | $0 | $3.8M |
The thesis
The Honest Company's turnaround is modestly more likely to lead the S&P 500 than lag it over three months, because margins are at a record and management raised the 2026 outlook. The fourth-quarter report, expected around March 2027, settles whether organic revenue growth lands in the 6–7% range the company now guides to for the full year.
The third-quarter report on 5 November 2026 showed organic revenue up 9.2% to $79.3 million and an underlying adjusted gross margin of 48.9%. Reported revenue fell 8.6% to $84.6 million because of the company's planned exits from low-margin lines under its Powering Honest Growth strategy. The shares closed at $4.80 on 12 November 2026, down from $5.10 on 11 November 2026 and above the $4.44 close on 5 November 2026.
A slowdown in retail sales is the main new weight on the case. An Earnings Whispers review of the 5 November 2026 call reports that tracked consumption grew 1.3% in the third quarter, from roughly 8% in both the first and second quarters. It also reports that diaper consumption fell 27% and that management now calls the diaper pressure structural. Management attributed most of the slowdown to Prime Day moving into the second quarter.
Bullish and bearish views on The Honest Company, Inc.
The bull case on The Honest Company, Inc. (HNST), in brief: organic growth accelerated. The bear case: retail consumption slowed sharply.
Bull case
- Organic growth accelerated. Third-quarter organic revenue rose 9.2% to $79.3 million from $72.6 million a year earlier (Form 8-K, 5 November 2026). Second-quarter organic growth was 6.7%.
- Underlying margin set a record. Underlying adjusted gross margin was 48.9%, up 1,160 basis points from 37.3% a year earlier and above 43.8% in the second quarter (Form 8-K, 5 November 2026). Reported gross margin was 45.0%.
- Management raised the outlook. The 2026 guide is now organic growth of 6–7% (prior 5–7%), adjusted gross margin of 45.5–46.5% (prior mid-40s), adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $25–26 million (prior $23–25 million) and revenue of $322–325 million (prior $319–325 million).
- Cash is large and funds buybacks. Cash was $103.0 million with no debt on 30 September 2026, and nine-month free cash flow was $30.5 million against negative $4.5 million a year earlier. The board approved a new repurchase program of up to $30 million on 30 October 2026. The prior $25 million program bought about 7.2 million shares at a weighted average of $3.47.
- A post-report analyst raised its target. B. Riley reiterated Buy and raised its price target to $5.50 on 6 November 2026, a level above the $4.80 close on 12 November 2026.
Bear case
- Retail consumption slowed sharply. Tracked consumption grew 1.3% in the third quarter, while organic revenue grew 9.2% (Earnings Whispers review of the call, 5 November 2026). If shipments to retailers outran shopper purchases, fourth-quarter organic growth has to come from sales to shoppers.
- Diapers are a structural drag. Diaper consumption fell 27% in the third quarter, a steeper decline than the 9.6% fall in the first quarter, per the same review. Reported revenue of $84.6 million was down 8.6% from $92.6 million.
- Headline earnings overstate operating earnings. Third-quarter diluted earnings per share of $0.81 include an $89.4 million non-cash tax benefit from releasing a valuation allowance. Underlying adjusted net income was $3.1 million and underlying adjusted EBITDA was $6.3 million, a 7.9% margin (Form 8-K, 5 November 2026).
- Spending steps up and the revenue ceiling is unchanged. Marketing rose 20% to $17.7 million in the third quarter, and management flagged further marketing and selling, general and administrative (SG&A) increases for the fourth quarter. The top of the revenue range stayed at $325 million while the low end rose from $319 million to $322 million.
- A labeling lawsuit is pending. A proposed class action over "hypoallergenic" labeling was reported on 5 November 2026. No damages figure or ruling has been reported.
Price setup
The shares closed at $4.80 on 12 November 2026. That is below the 50-day average of $5.07 and above the 200-day average of $3.88, both as of that close. The 3-month price change is −0.8%, against a close of $4.84 on 14 August 2026.
The 52-week intraday high is $6.01, set on 4 September 2026, and the last close is 20.1% below it. The 52-week closing low is $2.10, from 12 February 2026. Closes since the report ran $4.44 on 5 November 2026, $4.67 on 6 November 2026, $5.17 on 9 November 2026, $5.20 on 10 November 2026, $5.10 on 11 November 2026 and $4.80 on 12 November 2026. The post-report gain has mostly been given back in the last two sessions.
Insider selling is steady. SVP Thomas Sternweis filed a Form 4 on 10 November 2026 for a 25,000-share open-market sale on 9 November 2026 under a Rule 10b5-1 plan. His earlier 25,000-share sales were on 14 September 2026 and 8 October 2026. On 20 August 2026, Chief Executive Officer Carla Vernon sold 117,893 shares under a 10b5-1 plan, the same day she received a grant of 362,068 shares (Form 4, filed 24 August 2026). Many 2026 Form 4 sales at the company are tied to vesting stock units.
Catalysts ahead
- ~March 2027 (est.): Fourth-quarter and full-year 2026 results. Settles whether 2026 organic growth lands in the guided 6–7% range and whether adjusted gross margin reaches 45.5–46.5%, and shows whether retail consumption recovered from the third-quarter slowdown.
What would change the view
A daily close below $4.70, which would give back most of the gain since the $4.44 close on 5 November 2026, the day of the third-quarter report. A cut to the 2026 outlook (6–7% organic growth, 45.5–46.5% adjusted gross margin) would also break the case.
The risks this note tracks, each with what would confirm it:
- Retail consumption stays weak and shipments to retailers fall back toward shopper demand, slowing organic growth. Confirmed by: fourth-quarter organic growth implying a full year below the 6–7% guide, or tracked consumption growth again near the 1.3% of the third quarter.
- Diaper decline deepens and drags reported revenue below the guided range. Confirmed by: 2026 revenue reported below the $322 million low end of the guide, or a further cut to diaper expectations on the next call.
- Higher fourth-quarter marketing and SG&A spending narrows earnings even as sales grow. Confirmed by: full-year adjusted EBITDA reported below the $25–26 million guided range.
- The 'hypoallergenic' labeling class action leads to costs or label changes. Confirmed by: a court filing, settlement or company disclosure of a reserve or product relabeling.
What it trades with
The shares trade with small-cap consumer staples and personal-care companies, and with retailer demand for baby products. Diaper sales are the weakest category and a drag on reported revenue. Tariff costs and refunds on imported goods affect margins, and the company says its outlook reflects current tariff levels and mitigation measures (Form 8-K, 5 November 2026). Buybacks shrink the share count, which supports per-share results whatever sales do.
The evidence, claim by claim (8)
- Third-quarter 2026 revenue was $84.6 million, down 8.6%; organic revenue was $79.3 million, up 9.2%. The Honest Company third-quarter 2026 results, Form 8-K Exhibit 99.1 · as of
- Underlying adjusted gross margin was 48.9%, up 1,160 basis points from 37.3% a year earlier; reported gross margin was 45.0%. The Honest Company third-quarter 2026 results, Form 8-K Exhibit 99.1 · as of
- 2026 outlook raised: revenue $322–325 million (prior $319–325 million), organic growth 6–7% (prior 5–7%), adjusted gross margin 45.5–46.5% (prior mid-40s), adjusted EBITDA $25–26 million (prior $23–25 million). The Honest Company third-quarter 2026 results, Form 8-K Exhibit 99.1 · as of
- Third-quarter diluted EPS was $0.81 including an $89.4 million non-cash tax benefit; underlying adjusted net income was $3.1 million and underlying adjusted EBITDA was $6.3 million. The Honest Company third-quarter 2026 results, Form 8-K Exhibit 99.1 · as of
- Cash of $103.0 million with no debt; nine-month free cash flow of $30.5 million versus negative $4.5 million a year earlier. The Honest Company third-quarter 2026 results, Form 8-K Exhibit 99.1 · as of
- Board approved a new share repurchase program of up to $30 million; the prior $25 million program bought about 7.2 million shares at a weighted average of $3.47. The Honest Company third-quarter 2026 results, Form 8-K Exhibit 99.1 · as of
- Tracked consumption grew 1.3% in the third quarter versus roughly 8% in each of the first two quarters; diaper consumption fell 27%; marketing rose 20% to $17.7 million. Earnings Whispers review of the third-quarter 2026 call, via Finviz · as of
- B. Riley reiterated Buy and raised its price target to $5.50. B. Riley Securities note, reported 6 November 2026 · as of
Sources